Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression
- PMID: 9180827
Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression
Abstract
Background: Buspirone has previously been reported to be effective in the augmentation of the antidepressant effect of serotonin selective re-uptake inhibitors (SSRIs) in depressed outpatients. We report on buspirone augmentation of SSRIs in severe treatment-refractory depression in inpatients.
Methods: A retrospective chart review was undertaken of patients diagnosed with DSM-III-R major depression and treated at our inpatient unit. All 14 patients had been given structured depression rating scales before and after addition of buspirone to a SSRI.
Results: Patients had previously failed multiple trials of antidepressants, often including lithium and/or thyroid augmentation, as well as, in 12 cases, electroconvulsive therapy. However, augmentation of an SSRI with buspirone led to a rapid and significant improvement in depression in 6 of 14 (43%) patients.
Conclusion: Despite the limitations of the study design, our results support previous work suggesting the need for further controlled research on the use of buspirone in the augmentation of the antidepressant response to the SSRIs.
Similar articles
-
Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.Int Clin Psychopharmacol. 1998 Mar;13(2):83-6. doi: 10.1097/00004850-199803000-00005. Int Clin Psychopharmacol. 1998. PMID: 9669189 Clinical Trial.
-
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.J Clin Psychiatry. 2001 Jun;62(6):448-52. doi: 10.4088/jcp.v62n0608. J Clin Psychiatry. 2001. PMID: 11465522 Clinical Trial.
-
A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.J Clin Psychiatry. 1998 Dec;59(12):664-8. J Clin Psychiatry. 1998. PMID: 9921700 Clinical Trial.
-
New approaches to the treatment of refractory depression.J Clin Psychiatry. 2000;61 Suppl 1:26-32. J Clin Psychiatry. 2000. PMID: 10703760 Review.
-
Anxiolytic antidepressant augmentation.J Clin Psychiatry. 1998;59 Suppl 5:42-8; discussion 49-50. J Clin Psychiatry. 1998. PMID: 9635547 Review.
Cited by
-
An Evidence-Based Approach to Augmentation and Combination Strategies for: Treatment-Resistant Depression.Psychiatry (Edgmont). 2006 Jul;3(7):42-61. Psychiatry (Edgmont). 2006. PMID: 20975817 Free PMC article.
-
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.Int J Neuropsychopharmacol. 2020 Dec 3;23(9):587-625. doi: 10.1093/ijnp/pyaa033. Int J Neuropsychopharmacol. 2020. PMID: 32402075 Free PMC article.
-
A review of vilazodone, serotonin, and major depressive disorder.Prim Care Companion CNS Disord. 2014;16(1):PCC.13r01554. doi: 10.4088/PCC.13r01554. Epub 2014 Jan 9. Prim Care Companion CNS Disord. 2014. PMID: 24940527 Free PMC article.
-
Future antidepressants: what is in the pipeline and what is missing?CNS Drugs. 2004;18(11):705-32. doi: 10.2165/00023210-200418110-00002. CNS Drugs. 2004. PMID: 15330686 Review.
-
Vilazodone for the Treatment of Depression: An Update.Chonnam Med J. 2016 May;52(2):91-100. doi: 10.4068/cmj.2016.52.2.91. Epub 2016 May 20. Chonnam Med J. 2016. PMID: 27231672 Free PMC article. Review.